Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
07:49pm, Monday, 02'nd May 2022 Benzinga
Myovant Sciences Ltd (NYSE: MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
04:05pm, Monday, 02'nd May 2022
Myovant Sciences Ltd (NYSE: MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
11:10pm, Friday, 29'th Apr 2022 GlobeNewswire Inc.
BASEL, Switzerland, April 29, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVY
Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates
09:45pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 24.49% and 4.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant: Poised To Overcome Regulatory Issues
12:16pm, Tuesday, 26'th Apr 2022
The steep decline in Myovant Sciences share price is due to an FDA notice regarding relugolix label expansion for endometriosis. Irrespective of the FDA decision, I strongly believe that relugolix wil
BASEL, Switzerland, April 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced it will host a webcast and conference call to discuss corporate updates and financial results for
Myovant Sciences provides an update on a supplemental new drug
11:03am, Saturday, 16'th Apr 2022
Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced an update for an sNDA for MYFEMBREE, which is designed to manage severe to moderate pain linked to endometriosis. According to the ong
SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12
07:32pm, Wednesday, 13'th Apr 2022 Benzinga
SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences (NYSE:MYOV) and lower its price target from $19.00 to $12.00.
Shares of Myovant Sciences are trading up 8.08% over the
Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
05:47pm, Wednesday, 13'th Apr 2022
Shares of Myovant Sciences plunged this week after a regulatory setback for Myfembree. No reasons were provided by the FDA yet, and the deficiency letter comes as a big surprise.
FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA
06:47pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Though the FDA identified deficiencies in Myovant's (MYOV) Myfembree sNDA for managing endometriosis-associated pain, a final decision on the application is yet to be communicated.
Why Myovant Sciences Stock Is Crashing Today
03:49pm, Tuesday, 12'th Apr 2022 The Motley Fool
The FDA has identified deficiencies with Myovant's regulatory filing for Myfembree.
FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA
03:47pm, Tuesday, 12'th Apr 2022
Though the FDA identified deficiencies in Myovant's (MYOV) Myfembree sNDA for managing endometriosis-associated pain, a final decision on the application is yet to be communicated.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease
Aeglea BioTherapeutics Inc (NAS
Why Myovant Sciences Stock Is Crashing Today
11:49am, Tuesday, 12'th Apr 2022
The FDA has identified deficiencies with Myovant's regulatory filing for Myfembree.
What's Going On With Myovant Sciences Stock Today?
09:32am, Tuesday, 12'th Apr 2022
Myovant Sciences Ltd (NYSE: MYOV) shares are trading significantly lower Tuesday after the company and Pfizer Inc (NYSE: PFE) announced an update on the Supplemental New Drug Application for MYFEMBR
